HIV

Scientists have developed a structure-based vaccine design that can jumpstart an effective immune response to HIV by rapidly offsetting antibodies against the virus, which so far have been unsuccessful.

Gilead Sciences, Inc.  announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for the treatment of HIV. Descovy is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. Descovy is not indicated for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.

Researchers have identified an enzyme that is likely to lower the risk of heart related diseases caused by antiviral medicines used for human immunodeficiency virus (HIV).

A new technique developed by a team of chemists at Stanford University has shown promise to be thousands of times more sensitive than current techniques to diagnose diseases whether it is a cancer or a virus like HIV.

An antidepressant can improve decision-making and reaction time, and suppress inflammation in people with HIV-associated cognitive impairment, new research has found.

A single dose of the drug zoledronic acid was found to inhibit bone loss that is common in HIV-infected patients on antiretroviral therapy (ART), according to results of a phase two clinical trial.

An anti-retroviral (ARV) drug sometimes included in treatments to prevent mother-to-child HIV transmission during pregnancy may have adverse effects on infant development, new research has found.

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced it has agreed to purchase Bristol-Myers Squibb’s late stage HIV R&D assets. In a separate deal, ViiV Healthcare has agreed to acquire Bristol-Myers Squibb’s HIV portfolio of pre-clinical and discovery stage research assets. Each deal is subject to clearance by the regulatory authorities and is expected to complete in early 2016.